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Purpose: Use of theT cell-dependent neoantigen bacteriophageΦX 174 has been described
since the 1960s as a method to assess specific antibody response in patients with primary
immunodeficiencies. We reviewed a cohort of patients at Duke University Medical Center
who received immunization with bacteriophage and report the clinical utility and safety of
the immunization, as well as patient characteristics.
Methods: A retrospective chart review was performed of all Duke Immunology Clinic
patients (pediatric and adult) who received immunizations with bacteriophage, from 1976
to 2012. Subjects were selected for inclusion if their diagnosis at the time of bacteriophage
was either presumed or confirmed common variable immunodeficiency (CVID), hypogam-
maglobulinemia, transient hypogammaglobulinemia, or antibody deficiency unspecified.
Follow up post-immunization was also recorded.
Results: One hundred twenty-six patients were identified, 36 adults and 90 pediatric
patients. Diagnoses prior to bacteriophage were CVID (n=100), hypogammaglobuline-
mia (n=23), and antibody deficiency (n=3). Post-immunization diagnoses were CVID
(n=65), hypogammaglobulinemia (n=19), unknown (n=23), no primary immune defi-
ciency (n= 10), and other primary immunodeficiency (n=9). Seventy-five patients had
abnormal bacteriophage results, 37 were normal, and 14 were borderline.There were 257
recorded administrations of the immunization. Information was available on adverse reac-
tions for 171 administrations. Fourteen immunizations were associated with minor adverse
events. Nineteen patients stopped their immunoglobulin replacement therapy based on
reported normal responses to immunization.
Conclusion: Bacteriophage ΦX 174 immunization is a safe, well-tolerated, and clinically
useful method to assess antibody response in patients with suspected antibody-mediated
immunodeficiencies, particularly those who are on immunoglobulin replacement therapy
at the time of immunization.
Keywords: common variable immunodeficiency, bacteriophage ΦX 174, primary immunodeficiency,
hypogammaglobulinemia
INTRODUCTION
Bacteriophage ΦX 174 is a T cell dependent neoantigen first
described by Uhr et al., where it was used to assess antibody pro-
duction in guinea pigs (1). This “potent antigen” only infects its
host strain of E. Coli C and not mammalian cells. When injected
intravenously, two methods of assessment are used to determine its
effect: clearance of phage from the blood and in vitro measurement
of phage neutralization by IgM antibodies after the primary immu-
nization and by IgG antibodies after the second immunization (2).
In 1966, Ching et al. described the use of the immunization to
assess eight children with hypogammaglobulinemia and compare
them to healthy controls (2). They were able to assess clearance
of phage from the bloodstream, as well as IgM and IgG antibody
responses (2). Antibody production is measured as a logarithmic
neutralization factor, or K value (Kv), which represents the rate of
inactivation of phage (1, 3). A majority of the eight patients they
evaluated had responses of reduced magnitude, as well as defects
in isotype switching (2).
In 1971, Ochs et al. evaluated 26 patients with various types
of primary immunodeficiency, including eight with antibody
deficiencies, by injecting them with bacteriophage ΦX 174 (3).
Most patients received at least a primary and secondary immu-
nization; many also received tertiary and quaternary immuniza-
tions to study their response (3). They were compared to nor-
mal controls. Of the patients with unspecified antibody defi-
ciency, the majority had depressed responses to phage, little,
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or no demonstrable isotype switch from IgM to IgG after sec-
ondary or tertiary immunizations, and required immunoglobulin
replacement therapy (3).
In 1975, Wedgwood et al. reported their experience with bacte-
riophageΦX 174 immunization for immune assessment of specific
antibody production as “the single most useful antigen for the
systemic study of antibody responses in man.” (4) They further
classified the“normal”response, as well as classifying the abnormal
response into Types 0 through 5, based upon the antibody amount,
immunoglobulin class produced, and memory amplification in
the primary and secondary responses. The same group was fur-
ther able to characterize phage responses by developing an ELISA
technique, comparable to the neutralization assay, which allowed
them to directly measure immunoglobulin isotypes and specific
antibody subclasses (5). They confirmed the normal sequence of
immunoglobulin class antibody responses to immunization with
phage, as well as the characteristic memory response, amplifica-
tion, and isotype switching that occur after secondary and tertiary
immunization (5). More recently, the response to immuniza-
tion with bacteriophage ΦX 174 in 10 patients diagnosed with
adenosine deaminase deficiency (ADA) before and after various
treatments was evaluated for specific antibody responses after
treatment. The authors determined that patients treated with
bone marrow transplantation or PEG–ADA showed improvement
in their bacteriophage specific antibody response, as opposed to
patients treated with red blood cell transfusions, who continued
to exhibit severely depressed responses (6). In addition, Buck-
ley et al. have used bacteriophage immunization response as a
means to evaluate B cell function in post-transplantation for severe
combined immunodeficiency (SCID) patients, thus allowing for a
more definitive post-transplant treatment plan (7).
Common variable immunodeficiency is a clinical syndrome
that likely includes many different genetic defects and has a broad
spectrum of clinical and laboratory manifestations. It is charac-
terized by the presence of low or absent serum immunoglobulin
G and IgA and/or IgM despite the presence of circulating B
cells. Patients with common variable immunodeficiency (CVID)
may have a constellation of clinical findings including recurrent
infections, autoimmunity, predilection toward certain malignan-
cies, and lymphoproliferation of predominantly the lung and/or
gastrointestinal tract (8, 9). Currently, the Pan-American Group
for Immunodeficiency (PAGID) and the European Society for
Immunodeficiencies (ESID) define probable CVID as “serum IgG
and IgA at least two SDs below the mean with the following crite-
ria: (1) onset of immunodeficiency at >2 years of age; (2) absent
isohemagglutinins and/or poor response to vaccines; (3) defined
causes of hypogammaglobulinemia have been excluded” (10).
More recently, revised diagnostic criteria have been proposed with
a greater emphasis on clinical presentation, as well as presenting
criteria for initiating immunoglobulin replacement (11).
Bacteriophage ΦX 174 is still considered experimental and
requires an investigational new drug (IND) approval and an insti-
tutional review board approved protocol for its administration.
However, it is the only neoantigen that has been well studied
to assess antibody responses. The fact that it is a neoantigen
allows for the appropriate evaluation of patients with a sus-
pected immune deficiency, in particular CVID, who are already
on immunoglobulin replacement therapy. This is due to the
lack of natural protective antibody to bacteriophage ΦX 174 in
humans, therefore not present in commercial immunoglobulin
replacement products. Furthermore, the geography of the pooled
donors does not weigh into consideration for bacteriophage
immunization (12).
We performed a retrospective chart review of all Duke
Immunology Clinic patients (pediatric and adult) who received
immunization with bacteriophage, from 1976 to 2012. Subjects
were selected for inclusion if their diagnosis at the time of bac-
teriophage was either presumed or confirmed CVID, hypogam-
maglobulinemia, transient hypogammaglobulinemia, or antibody
deficiency unspecified. Our primary goal was to report clinical
utility and safety of the immunization, as well as the patient
characteristics of our cohort.
MATERIALS AND METHODS
All patients received bacteriophage ΦX 174 immunization (FDA
number BB-IND 5620) after receiving informed consent for inves-
tigational use in accordance with Duke University Medical Center
institutional review board approval and protections for human
subject research considerations. Patients were immunized with
0.022 mL/kg of bacteriophageΦX 174 given intravenously. Periph-
eral blood was collected immediately prior to the first immu-
nization, 15 min after the first immunization and thereafter at 7,
14 days, and 4 weeks later to assess the primary antibody response.
A second immunization was given 6–10 weeks after the primary
immunization per protocol. A peripheral blood sample was col-
lected prior to the second immunization. The dose of the second
immunization was given IV at 0.022 mL/kg just as the primary,
with peripheral blood samples collected at 7 and 14 days after the
second immunization and then again at 4 weeks after. Two immu-
nizations formulated the standard protocol for antibody assess-
ment, although some patients did receive tertiary immunization
6 months to years later as part of ongoing evaluations.
All peripheral blood samples were sent to the Immunology
Diagnostic Laboratory at Seattle Children’s for determination
of phage clearance, antibody neutralization, and isotype switch
response prior to and after immunization. Bacteriophage samples
were processed as previously described by Wedgwood et al. (4).
When given intravenously, bacteriophage stays in the intravascu-
lar space until clearance occurs (4). The agar overlay method is
used on the various samples to determine the number of plaque-
forming units (PFU) of phage per milliliter of serum and therefore
assess bacteriophage clearance (4). To assess antibody production,
either a neutralization assay or ELISA is used. The neutralization
assay incubates a standard amount of bacteriophage with diluted
serum and uses the agar overlay method at specific intervals to
determine the amount of residual bacteriophage (4). The Kv (rate
of inactivation) is calculated using a standard formula (4). Isotype
switch response is determined using 2-mercaptoethanol suscepti-
bility; gel filtration demonstrates a macroglobulin peak (IgM) and
another peak representative of IgG (4).
We performed a retrospective chart review on all the patients
who have been immunized with bacteriophage at our institu-
tion, selecting the patients whose reason for having bacterio-
phage performed was listed as CVID, hypogammaglobulinemia,
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transient hypogammaglobulinemia, or antibody deficiency. Dates
of immunization ranged from 1976 to 2012.
RESULTS
PATIENT DEMOGRAPHICS
One hundred twenty-six patients were identified. At the time of
immunization, 90 patients were pediatric and 36 were adults. Prior
to immunization with bacteriophage, 100 patients had a diag-
nosis of CVID, 23 had a diagnosis of hypogammaglobulinemia
(transient or other), and 3 had a diagnosis of antibody deficiency
(Table 1).
Complete clinical history for interpretation was available for
109 of the 126 patients. All subject records noted recurrent
infections of varying severity. Eighty-eight subjects had recur-
rent sinopulmonary infections. Seven had sepsis and/or bac-
teremia. Fifteen had severe bacterial infections, which consisted
of pericarditis, meningitis, severe pneumonia, septic arthritis,
osteomyelitis, psoas abscess, and complicated otitis media. Five
subjects had skin infections or abscesses noted in their clinical his-
tory. Thirteen had severe viral infections, consisting of recurrent
HSV, EBV, severe VZV, RSV requiring intubation, death from dis-
seminated enterovirus, and severe warts. Three patients had PJP
pneumonia, and three patients had pathogenic infections due to
other less common infectious organisms, including candida and
strongyloides (Figure 1).
LABORATORY FEATURES
Immunoglobulin values were recorded from the time the patient
received bacteriophage, or, if available, from the earliest patient
encounter available. For some patients, the only immunoglobulin
values available were obtained after immunoglobulin replacement
therapy had already been initiated. Forty-five patients had an IgG
<300 mg/dL; one of these was on replacement therapy. Forty-five
patients had IgG levels from 300 to 499; three of those patients were
on replacement therapy. Fourteen patients had IgG levels from
Table 1 | Demographics.
Diagnosis Pre-test diagnosis Post-test diagnosis
(n=126) (n=126)
Total Pediatric (%) Total Pediatric (%)
CVIDa 100 65/100 (65) 65 44/65 (68)
Hypogammaglobulinemia
(transient or other)
23 22/23 (96) 19 15/19 (79)
Antibody deficiency NOS 3 3/3 (100) 0 –
No PID − 10 3/10 (30)
Otherb − 9 7/9 (78)
Unknown − 23 20/23 (91)
aDiagnosis of CVID as listed in the medical record – 44 patients met ESID criteria
for CVID at the pre-test diagnosis, 38 did not, and 44 had incomplete data to
assess.
bOther, hyper IgM syndrome, IgA deficiency, PNP deficiency, CID, and unspecified
PID.
500 to 699; four of those were on replacement therapy. Twenty
patients had IgG >700; 12 of those were on replacement therapy.
Two patients did not have immunoglobulin levels available. Other
than the 20 patients known to be on replacement therapy, all values
were obtained prior to initiation of IV or subcutaneous Ig. Ninety
patients had baseline IgG at or under 499 mg/dL.
In the group of patients with IgG <300, 42/45 had either IgA
or IgM below two SDs for age. In the group with IgG from 300 to
499, 38/45 had low IgA or IgM. In the group from 500 to 699, 9/14
had concomitant low IgA or IgM. In the group with IgG >700,
11/20 had low IgA or IgM levels (Table 2).
Eighty-eight patients had in vitro studies of lymphocyte pro-
liferation in response to both mitogen and antigen stimulation
performed. Of those, 10/88 had abnormalities in both mitogens
and antigens, 1 had an abnormal response to mitogens only, 19
had abnormal responses to antigens, and 58 were normal. Twelve
patients had proliferation performed only in response to mitogens,
and of those, 4/12 were abnormal (Table 3).
DIAGNOSES AND BACTERIOPHAGE RESULTS
Out of the 126 patients, 37 had normal bacteriophage antibody
responses following primary and secondary immunizations, 75
were abnormal, and 14 patients had borderline results. The median
Kv (representative of the rate of inactivation of bacteriophage) of
the abnormal patients was well below the range for normal controls
(Figure 2). No patient had abnormal clearance of bacteriophage
ΦX 174. Patients were classified as borderline if their response was
described as “near normal” or if their Kv and/or percentage of IgG
post-secondary immunization were at the lowest limit of cutoff
for a normal result.
Failure to make an appropriate amount of IgG after secondary
immunization indicates an inability to isotype switch from IgM
to IgG (3). Of the 75 abnormal patients, 38/75 exhibited both
low total antibody amounts as well as abnormal ability to isotype
switch from IgM to IgG after secondary immunization. Twenty-
four of those 38 made zero IgG after the secondary immunization.
Thirty-six of the 75 abnormal patients had low total antibody
amounts, but they were able to adequately isotype switch from
FIGURE 1 | Infection data historical infections in study patients. One
hundred nine patients’ records were complete to evaluate relevant infection
history. The types of infections are shown among the patients evaluated
with bacteriophage immunization. See text for greater detail.
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IgM to IgG. One patient out of the 75 had a quantitatively normal
amount of antibody but failed to isotype switch (Table 4).
After the results of the bacteriophage immunizations were
known, 65 patients were diagnosed as having CVID, 19 were diag-
nosed as having hypogammaglobulinemia (transient or other), 23
were unknown, 10 were determined to have no primary immun-
odeficiency, and 9 had a diagnosis of “other” (Table 1). “Other”
included Hyper IgM syndrome, IgA deficiency, PNP deficiency,
combined immunodeficiency, and unspecified primary immune
deficiency. The 23 patients who were unknown were simply lost
to follow up or had no records available; it is possible that they
also carried diagnoses of CVID. Nineteen patients (15%) who
had been on immunoglobulin replacement had it discontinued by
their treating physician after a normal bacteriophage result was
obtained.
We further grouped bacteriophage results in terms of immuno-
logic parameters. Of the 45 patients with IgG<300, 31 (69%) were
abnormal and 7 (16%) were borderline. Of the 45 patients with IgG
levels from 300 to 499, 24 (57%) were abnormal and 5 (11%) were
borderline. Of the 14 patients with IgG 500–699, 9 (64%) were
abnormal and 0 were borderline. Finally, of the 20 patients with
IgG>700, 10 (50%) were abnormal and 2 (0.1%) were borderline.
Of note, 12/20 patients in this group were on immunoglobulin
replacement therapy at the time their IgG level was drawn, likely
accounting for their normal IgG levels but abnormal response
(Table 2).
It is also helpful to look at patient bacteriophage ΦX 174
immune response in relation to recorded patient antibody
response to traditional immunizations. Out of the 75 patients with
abnormal bacteriophage results, 56 had baseline tetanus and diph-
theria antibody titers recorded prior to initiation of immunoglob-
ulin replacement. For tetanus, 45/56 (80%) had abnormal base-
line titers. Of those 45, 23 received a booster vaccination, and
19/23 had abnormal titers post-booster vaccination. For diphthe-
ria, 48/56 (86%) had abnormal baseline titers, 23 received booster
vaccination, and 19/23 as well remained abnormal after receiv-
ing the booster. Only 18 patients with abnormal bacteriophage
had data available regarding pneumococcal titers. Of those, 15/18
were abnormal at baseline, 13 received Pneumovax, and 10/13
continued to have low titers after booster vaccination (Table 5).
SAFETY
Data were available on adverse reactions for a smaller cohort of
patients. One hundred twenty-six patients received primary and
secondary immunization, and 13 patients also received a tertiary
immunization, representing 265 recorded administrations of bac-
teriophage ΦX 174 immunization. Data were recorded regarding
immediate reactions (within 24 h after immunization) for 171 out
of 265 administrations of the immunization, while for delayed
reactions (those occurring 24–72 h after the immunization) data
were available for 53 out of 265 administrations. There were a
total of four immediate reactions recorded with administration of
bacteriophage: rash (1/171), headache (1/171), and fever (2/171).
Therefore, 167/171 (94%) administrations of bacteriophage had
no immediate reaction noted.
There were a total of 10 patients reporting delayed adverse
events, frequently consisting of multiple discrete symptoms asso-
ciated with a single immunization. Each discrete symptom was
counted toward total adverse events in the delayed period. Thus for
53 administrations of bacteriophage, delayed symptoms included
rash (2/53), fever (4/53), itching (2/53), nausea/vomiting (2/53),
sweats (1/53), and headache (4/53) times. Therefore, 43/53 (81%)
administrations of bacteriophage were tolerated without a delayed
reaction after immunization.
Data on adverse reactions are limited by the retrospective nature
of this study. Information on reactions was obtained from patient
questionnaires that were given out at the time of immunization
and then requested to be mailed back. This is likely the primary






both mitogens and antigens
88 − –
Both abnormal 10 9 1
Mitogens abnormal 1 1 0
Antigens abnormal 19 8 4
Both normal 58 35 6
Only mitogens performed 12 6 1
Abnormal mitogens 4 3 0
Only antigens performed 0 − –
Lymphocyte proliferation. Shows the number of patients who had lymphocyte
proliferation studies done and bacteriophage ΦX 174 results. Mitogens tested
were phytohemagglutinin (PHA), concanavalin A (ConA), and pokeweed mitogen
(PWM). Antigens tested were tetanus and candida.
Table 2 | Serum immunoglobulin levels prior to immunization.
Parameter Patients (n=126) Low IgA or IgM On Ig replacementa Abnormal phage (n=75) Borderline phage
IgG <300 45 42 1/45 31 7
IgG 300–499 45 38 3/45 24 5
IgG 500–699 14 9 4/14 9 0
IgG >700 20 11 12/20 10 2
Ig not available 2 − – 1 0
aNumber of patients on Ig replacement when immunoglobulins were drawn.
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reason that data were available for only 65% of the administrations
of the vaccine. We are unable to say whether the patients who did
not return questionnaires experienced adverse events, but in the
cohort that we have available the rate seems quite low and the
effects mild.
DISCUSSION
To the best of our knowledge, this is the largest reported cohort
of patients with suspected antibody-mediated immunodeficiency
who received diagnostic immunization with bacteriophage ΦX
174. This large report additionally shows results of bacteriophage
ΦX 174 immunization across both pediatric and adult patients.
There were no relevant differences in the results or safety data
between pediatric and adult populations. All of the subjects in
the study underwent bacteriophageΦX 174 immunization with a
clear indication for an immunologic evaluation based on histories
FIGURE 2 | Abnormal bacteriophage ΦX 174 results bacteriophage
immunization results. Graph showing the range of normal bacteriophage
(±2 SDs) and the median values for the abnormal patients. Values were
obtained 1, 2, and 4 weeks after the primary immunization, prior to
administering the secondary, and then 1, 2, and 4 weeks after
administration of the secondary immunization (4).
of recurrent or severe infections. Eighty-eight patients (70%) had a
documented history of sinopulmonary infections. Sinopulmonary
infections are the most frequent type of infection reported in
CVID, and often are the presenting symptom and impetus for eval-
uation (13). Fifteen patients (12%) had severe bacterial infections,
and 13 (10%) had severe viral infections. Severe viral infections
are not typically associated with CVID. The patient who died from
disseminated enteroviral infection was diagnosed with an unspeci-
fied primary immunodeficiency. Two patients with severe varicella
as well as HSV and EBV, respectively, had confirmed diagnoses of
CVID and normal in vitro lymphocyte proliferation responses.
Another patient with severe varicella was also diagnosed as hav-
ing CVID, but that patient had abnormal proliferative response to
mitogens and antigens. A fourth patient with severe varicella was
also diagnosed with CVID and, although he had normal in vitro
proliferative responses to PHA and ConA, his responses to poke-
weed mitogen, tetanus, and candida were low. The patient with
warts was diagnosed with CVID and had no T cell proliferation
abnormalities. The patient with severe RSV requiring intubation
was eventually diagnosed as having transient hypogammaglobu-
linemia of infancy, which is not unreasonable as RSV is known to
potentially cause severe disease in immunocompetent hosts. Only
109 patients had data available on their infectious history, so it is
possible that more of our cohort had sinopulmonary infections
and other infectious complications.
Although administration of bacteriophage ΦX 174 is labor
intensive and requires an IRB approval for investigational use, it is a
clinically useful diagnostic tool. Many of the patients in our cohort
had a diagnosis of CVID confirmed by abnormal bacteriophage
results. Of the 65 patients who had a confirmed post-test diagnoses
of CVID, 54 (83%) had abnormal phage results. Six (9%) were bor-
derline. Five patients (8%) were technically listed as having normal
results, but 3/5 were atypical with respect to the expected kinetics
of the antibody response or proportion of isotype switch. One of
those patients had an abnormal 4-week primary response but a
normal secondary and was overall considered normal. However,
this patient was also noted to have splenomegaly and immune
thrombocytopenic purpura, in addition to low immunoglobu-
lins and recurrent infections. Another subject was resulted as
normal due to a quantitatively normal overall response, but the
primary response was delayed and the proportion of isotype was
skewed to a predominant IgM secondary response. A third “nor-
mal” patient in the group had normal testing when measured by
Table 4 | Isotype switching in abnormal bacteriophage patients.















ABNORMAL BACTERIOPHAGE ΦX 174 N =75
IgG <300 12 8/12 18 1 0/31
IgG 300–499 12 7/12 12 0 3/24
IgG 500–699 7 3/7 2 0 2/9
IgG >700 6 5/6 4 0 6/10
IgG not available 1 1/1 0 0 0/1
Isotype switching. Breakdown of the 75 patients with abnormal bacteriophage results describing defect in antibody production, isotype switching, or both.
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Table 5 | Recorded specific antibody titers in patients with abnormal
bacteriophage results (n=75)a.
Parameter Number Abnormal Received Abnormal
(antibody patients with baseline booster after
titers) data available booster
Tetanus 56/75 45/56 23 19/23
Diphtheria 56/75 48/56 23 19/23
Pneumococcal 18/75 15/18 13 10/13
aValues obtained prior to initiation of Ig replacement.
ELISA, but when the test was performed by neutralization her
primary response was mildly low. The final two reported normal
results later confirmed diagnoses of CVID that had progressed
from IgA deficiency to CVID. Therefore, it is possible that the bac-
teriophage testing occurred too early in the disease process and
thus if performed later or repeated might have yielded abnormal
responses. In these examples, immunization with bacteriophage
ΦX 174 appears to highlight the utility of confirming whether or
not an antibody-mediated immune disorder is present.
Perhaps, the most useful application of bacteriophage ΦX 174
is in assessing patients who are already receiving immunoglob-
ulin replacement therapy. Since bacteriophage is a neoantigen,
therapeutic immunoglobulin preparations do not contain natural
antibodies to bacteriophageΦX 174, and therefore immunoglob-
ulin replacement therapy does not need to be discontinued in
order to perform the test. At times patients and physicians are
forced to choose between continuing a costly treatment that may
be unnecessary or stopping it with the risk that it may be essential
for keeping the patient healthy, in order to complete an accurate
assessment of their immune function. Nineteen patients in our
cohort had their immunoglobulin replacement therapy stopped
after having normal bacteriophage results. As bacteriophage is a
T cell-dependent neoantigen, a normal result does not necessar-
ily mean that the patient has adequate polysaccharide response,
and it is possible that IVIG may still be warranted. However, it
can be used as a discriminating diagnostic tool and may provide
reassurance about the relative safety of stopping Ig replacement
therapy.
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